广西田园生化IPO观察：高分红、低研发与合规风险并存

Group 1: Company Overview and IPO Progress - Guangxi Tianyuan Biochemical Co., Ltd. (referred to as "Tianyuan Biochemical") has completed its IPO counseling report and is officially targeting the capital market with annual revenue exceeding 1.7 billion yuan [1] - The company, founded in 1994, focuses on three main business segments: pesticide formulations, medicinal fertilizers, and smart agricultural machinery [5] - The company signed a counseling agreement in April 2022 with Guohai Securities as the counseling institution, optimizing its equity structure during the counseling period [7] Group 2: Financial Performance and Concerns - The company has shown a continuous increase in net profit over three years, with figures of 162 million yuan in 2022, 229 million yuan in 2023, and 249 million yuan in 2024 [3] - However, there are concerns regarding a revenue decline in 2024 and a drop in product prices across the board, with a significant 36.5% decrease in herbicide prices from 39.63 yuan/kg in 2022 to 25.16 yuan/kg in 2024 [12][13] - The company distributed a total of 221 million yuan in dividends in the two years leading up to the IPO, raising questions about the rationale behind such distributions prior to seeking 630 million yuan in fundraising [15][26] Group 3: Sales Model and Risks - The company relies heavily on a distribution network, with over 95% of revenue coming from distributors from 2022 to 2024, which poses risks such as management control issues and potential channel loss [10][12] - The pricing control has been challenging, as evidenced by the continuous decline in average selling prices of all main products during the reporting period [12][13] Group 4: Research and Development (R&D) Challenges - The company's R&D expenditure rates were 2.53%, 2.71%, and 4.24% from 2022 to 2024, consistently below the industry average of 4.98%, 5.29%, and 5.18% [15][17] - The company has justified its lower R&D spending by citing the high output from its medicinal fertilizer products, but this "catch-up" approach to R&D may raise concerns about its long-term innovation capabilities [19] Group 5: Compliance and Regulatory Issues - The company faces potential compliance issues, including 11,400 square meters of unlicensed property, which could be classified as illegal construction [20] - There have been administrative penalties related to the sale of counterfeit pesticides and misrepresentation of product origins, highlighting vulnerabilities in production quality control and supply chain management [23][25]